| 0000-00-00 |
|
|
|
External link to document |
| 2023-07-24 |
28 |
|
9,421,195, and 10,335,397 (“the HE Patents”); patents claiming a method
of treating IBS-D, U.S. Patent Nos. 8,309,569…; 195 Patent"), and claims 11-12 of U.S. Patent
No. 10,335,397 (the '"397 Patent"…9,421,195,
10,335,397 ("the HE Patents"), 8,309,569, and 10,765,667 ("the IBS-D Patents"…groups of patents:
patents claiming a method of treating hepatic encephalopathy, U.S. Patent Nos.
8,642,573…(“the IBS-D
Patents”); and patents claiming rifaximin in polymorphic form β, U.S. Patent Nos.
7,612, |
External link to document |
| 2024-04-11 |
71 |
Opinion |
claim 2 of U.S. Patent 8,309,569, claim 3 of U.S.
Patent 10,765,667, claim 4 of U.S. Patent 7,612,199, and… U.S. Patent
8,624,573, claim 6 of U.S. Patent 9,421,195, and claims 11
and 12 of U.S. Patent 10,335,397…claim 2 of the ’569
patent, claim 3 of the ’667 patent, claim 4 of the ’199 patent,
and claim 36 of the…streamlined
to three groups of patents:
• the ’573, ’195, and ’397 patents, directed to treating
… HE (“the HE patents”);
• the ’569 and ’667 patents, directed to treating IBS-D
with |
External link to document |
| 2024-05-10 |
73 |
|
claim 2 of U.S. Patent 8,309,569, claim 3 of U.S.
Patent 10,765,667, claim 4 of U.S. Patent 7,612,199, and…U.S. Patent
8,624,573, claim 6 of U.S. Patent 9,421,195, and claims 11
and 12 of U.S. Patent 10,335,397…claim 2 of the ’569
patent, claim 3 of the ’667 patent, claim 4 of the ’199 patent,
and claim 36 of …streamlined
to three groups of patents:
• the ’573, ’195, and ’397 patents, directed to treating
… HE (“the HE patents”);
• the ’569 and ’667 patents, directed to treating IBS-D
|
External link to document |
